Anna Hagström
We focus on understanding the pathogenetic mechanisms underlying leukemogenesis with a special focus on infant leukemia. In particular we are interested in unravelling the biological mechanisms that drive clonal evolution, the emergence of drug resistance, and the role of tumor heterogeneity in these processes, ultimately leading to new effective therapies. We use a combination of state-of-the-a
https://www.clinicalgenetics.lu.se/division-clinical-genetics/anna-hagstrom - 2025-07-11